Allergan to Pay $375M in Criminal Case Over Off-Label Marketing of Botox
A federal judge in Atlanta yesterday okayed a $375 million settlement of a criminal case by Allergan Inc. concerning the company’s marketing of Botox drug for off-label purposes not approved by the U.S. Food and Drug Administration.
Although Allergan denies wrongdoing, aside from one misdemeanor count over its marketing of the drug, the plea is significant because it was made by the parent company, U.S. Attorney Sally Quillian Yates tells the Prescriptions blog of the New York Times.
“If they get caught again, next time it’s a felony,” she said.
Last month, the company announced that it would pay another $225 million to settle a civil False Claims Act case over Botox by the Justice Department, notes Bloomberg.
An Associated Press article provides further details.
